Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Sven Tyge, Langkjer"'
Autor:
Noemia Afonso, Marina Cazzaniga, Xavier Pivot, Edgar Petru, Sven Tyge Langkjer, Valter Torri, Pedro Sánchez Rovira, Patricia Gomez, Guido Bocci, Piotr J. Wysocki, Elisabetta Munzone
Publikováno v:
Cazzaniga, M E, Munzone, E, Bocci, G, Afonso, N, Gomez, P, Langkjer, S, Petru, E, Pivot, X, Sánchez Rovira, P, Wysocki, P & Torri, V 2019, ' Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients : The PENELOPE Project ', Advances in Therapy, vol. 36, no. 2, pp. 381-406 . https://doi.org/10.1007/s12325-018-0844-4
Introduction: Metronomic chemotherapy (mCHT) is a treatment regimen in which drugs are administered frequently or continuously and that maintains low, prolonged, and pharmacologically active plasma concentrations of drugs to avoid toxicity associated
Autor:
Charlotte Buch Jensen, Peter Michael Vestlev, Erik Jakobsen, Hella Danø, Sven Tyge Langkjer, T. Dongsgaard, Adam Luczak, J. Neimann, Anne Sofie Brems-Eskildsen, Søren Linnet
Publikováno v:
Brems-Eskildsen, A S, Linnet, S, Danø, H, Luczak, A, Vestlev, P M, Jakobsen, E H, Neimann, J, Jensen, C B, Dongsgaard, T & Langkjer, S T 2021, ' Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer ', Acta Oncologica, vol. 60, no. 2, pp. 157-164 . https://doi.org/10.1080/0284186X.2020.1851045
Background: Metronomic treatment is hypothesized to be less toxic and more effective as compared to standard maximal tolerable dosing treatment in metastatic cancer disease. Material and methods: We tested the metronomic treatment principle with vino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2101a4cbcc0032e69ac0121949ed806f
https://vbn.aau.dk/da/publications/76bfbc2e-c9a4-4913-af91-571e16566305
https://vbn.aau.dk/da/publications/76bfbc2e-c9a4-4913-af91-571e16566305
Publikováno v:
Ugeskrift for laeger. 182(21)
In this review, we discuss isoflavones, which are bioactive selective estrogen receptor modulators shown to have therapeutic efficacy in reducing bone resorption and improving menopause symptoms in women with estrogen deficiency. The European Food Sa
Autor:
Ida Kappel Buhl, Troels Dreier Christensen, Anna Sofie Kappel Buhl, Ib Jarle Christensen, Eva Balslev, Ann Søegaard Knop, Bent Ejlertsen, Iben Kümler, Hella Danø, Adam Andrzej Luczak, Sven Tyge Langkjer, Søren Linnet, Erik Hugger Jakobsen, Jurij Bogovic, Vesna Glavicic, Ulla Hald Buhl, Steen Knudsen, Peter Buhl Jensen, Dorte Nielsen
Background Even with positive oestrogen receptor (ER+) status some advanced breast cancer (ABC) patients fail to benefit from endocrine therapy (ET). A method that previously predicted other drugs in various cancers was evaluated. Here multigene mark
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f74f0164074f9f5c285dc7b7b2cb16b
https://doi.org/10.21203/rs.2.10981/v1
https://doi.org/10.21203/rs.2.10981/v1
Autor:
S Filipović, Carlos H. Barrios, B Yao, Anil A. Joy, A. Chan, S Chia, S. Moran, Miguel Martin, Beverly Moy, Bent Ejlertsen, R De Boer, Y. Ye, Noa Ben-Baruch, Michael Gnant, Richard A. Bryce, David Cella, Lesley Fallowfield, Sven Tyge Langkjer, Suzette Delaloge, Noelia Martínez, Francis M. Senecal, Frankie A. Holmes, A. Ciceniene, Hiroji Iwata, Janine Mansi, Snezhana Smichkoska, Marc Buyse, A.H. Auerbach
Publikováno v:
Delaloge, S, Cella, D, Ye, Y, Buyse, M, Chan, A, Barrios, C H, Holmes, F A, Mansi, J, Iwata, H, Ejlertsen, B, Moy, B, Chia, S K L, Gnant, M, Smichkoska, S, Ciceniene, A, Martinez, N, Filipović, S, Ben-Baruch, N E, Joy, A A, Langkjer, S T, Senecal, F, de Boer, R H, Moran, S, Yao, B, Bryce, R, Auerbach, A, Fallowfield, L & Martin, M 2019, ' Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer : longitudinal analyses from the randomized phase III ExteNET trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 30, no. 4, pp. 567-574 . https://doi.org/10.1093/annonc/mdz016
BACKGROUND: We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET study, which demonstrated an invasive disease-free survival benefit of extended adju
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64ba1f22a813215af6018089c4ca9167
https://pure.au.dk/portal/da/publications/effects-of-neratinib-on-healthrelated-quality-of-life-in-women-with-her2positive-earlystage-breast-cancer(38fa4be9-a02a-4768-9c96-decbf86a9e95).html
https://pure.au.dk/portal/da/publications/effects-of-neratinib-on-healthrelated-quality-of-life-in-women-with-her2positive-earlystage-breast-cancer(38fa4be9-a02a-4768-9c96-decbf86a9e95).html
Autor:
T. Dongsgaard, Sven Tyge Langkjer, Lars Stenbygaard, Helle Lemvig Kruse, Julia Kenholm, Anne Sofie Brems-Eskildsen, Jeanette Dupont Jensen, Hella Danø, Bjørnar Gilje, Kim Wedervang, J. Neimann, Jürgen Geisler, Erik Hugger Jacobsen, Vesna Glavicic, Mie Grunnet, Annette Torbøl Brixen
Publikováno v:
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2019, ' The NAME trial : A direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer ', Future Oncology, vol. 15, no. 22, pp. 2561-2569 . https://doi.org/10.2217/fon-2019-0124
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2019, ' The NAME trial : a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer ', Future Oncology, vol. 15, no. 22, pp. 2561-2569 . https://doi.org/10.2217/fon-2019-0124
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2019, ' The NAME trial : a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer ', Future Oncology, vol. 15, no. 22, pp. 2561-2569 . https://doi.org/10.2217/fon-2019-0124
Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd3e68144dbea7113137cab419868c36
http://hdl.handle.net/10852/77735
http://hdl.handle.net/10852/77735
Autor:
Sven Tyge Langkjer, Søren Linnet, Tamás Lörincz, Anne Sofie Brems-Eskildsen, Kristina B. Kristoffersen
Publikováno v:
Brems-Eskildsen, A S, Kristoffersen, K B, Linnet, S, Lörincz, T & Langkjer, S T 2019, ' Efficacy and toxicity of eribulin treatment in metastatic breast cancer patients ', Acta Oncologica, vol. 58, no. 1, pp. 119-121 . https://doi.org/10.1080/0284186X.2018.1497301
Although the treatment of breast cancer has achieved numerous improvements, long-term survival for metastatic disease remains poor. The lines of chemotherapy are limited and there is no single acce...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f87345f38f38777fd881cd2703f1be93
https://pure.au.dk/portal/da/publications/efficacy-and-toxicity-of-eribulin-treatment-in-metastatic-breast-cancer-patients(067b9663-e667-4f9e-9e8a-37754ae48909).html
https://pure.au.dk/portal/da/publications/efficacy-and-toxicity-of-eribulin-treatment-in-metastatic-breast-cancer-patients(067b9663-e667-4f9e-9e8a-37754ae48909).html
Autor:
Adam Luczak, Søren Linnet, J. Neimann, A. S. Brems-Eskildsen, T. Dongsgaard, H. A. Nielsen, Sven Tyge Langkjer, E. H. Jacobsen, Peter Michael Vestlev, C. B. Jensen
Publikováno v:
European Journal of Cancer. 57:S19-S153
Publikováno v:
Rosvig, L H, Jensen, A B, Langkjer, S T & Knoop, A 2018, ' Carboplatin-regime som behandlingsmulighed til senstadie brystkræft ', Best Practice Oncology .
Aarhus University
Aarhus University
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::89a659a584091b1cd8fe2235804e1313
https://pure.au.dk/portal/da/publications/carboplatinregime-som-behandlingsmulighed-til-senstadie-brystkraeft(9a1ca169-65a4-4ff5-a705-c1b25d42a3a0).html
https://pure.au.dk/portal/da/publications/carboplatinregime-som-behandlingsmulighed-til-senstadie-brystkraeft(9a1ca169-65a4-4ff5-a705-c1b25d42a3a0).html
Autor:
Troels Dreier Christensen, Anna Sofie Kappel Buhl, Jurij Bogovic, Knud Mejer Nelausen, Ib Jarle Christensen, Eva Harder Brix, Ann Knoop, Else Svensson, Steen Knudsen, Sven Tyge Langkjer, Søren Linnet, Adam Luczak, Anker Jon Hansen, Peter Buhl Jensen, Eva Balslev, Erik Jakobsen, Dorte Nielsen, Bent Ejlertsen, Annie Rasmussen, Vesna Glavicic
Publikováno v:
Buhl, A S K, Christensen, T D, Christensen, I J, Nelausen, K M, Balslev, E, Knoop, A S, Brix, E H, Svensson, E, Glavicic, V, Luczak, A, Langkjer, S T, Linnet, S, Jakobsen, E H, Bogovic, J, Ejlertsen, B, Rasmussen, A, Hansen, A, Knudsen, S, Nielsen, D & Jensen, P B 2018, ' Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort : a retrospective-prospective blinded study ', Breast Cancer Research and Treatment, vol. 172, no. 2, pp. 391-400 . https://doi.org/10.1007/s10549-018-4918-4
Buhl, A S K, Christensen, T D, Christensen, I J, Nelausen, K M, Balslev, E, Knoop, A S, Brix, E H, Svensson, E, Glavicic, V, Luczak, A, Langkjer, S T, Linnet, S, Jakobsen, E H, Bogovic, J, Ejlertsen, B, Rasmussen, A, Hansen, A, Knudsen, S, Nielsen, D & Jensen, P B 2018, ' Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort : a retrospective-prospective blinded study ', Breast Cancer Research and Treatment, vol. 172, no. 2, pp. 391–400 . https://doi.org/10.1007/s10549-018-4918-4
Breast Cancer Research and Treatment
Buhl, A S K, Christensen, T D, Christensen, I J, Nelausen, K M, Balslev, E, Knoop, A S, Brix, E H, Svensson, E, Glavicic, V, Luczak, A, Langkjer, S T, Linnet, S, Jakobsen, E H, Bogovic, J, Ejlertsen, B, Rasmussen, A, Hansen, A, Knudsen, S, Nielsen, D & Jensen, P B 2018, ' Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort : a retrospective-prospective blinded study ', Breast Cancer Research and Treatment, vol. 172, no. 2, pp. 391–400 . https://doi.org/10.1007/s10549-018-4918-4
Breast Cancer Research and Treatment
PURPOSE: Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated the predictive value of a multigene mRNA-based drug response predictor (DRP) in the treatment of advanced BC with epiru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f4d0f127f0dafb654c610d7a725c80a
https://curis.ku.dk/portal/da/publications/predicting-efficacy-of-epirubicin-by-a-multigene-assay-in-advanced-breast-cancer-within-a-danish-breast-cancer-cooperative-group-dbcg-cohort(d94324d4-b6ee-484b-9f67-4ebcfeaf6560).html
https://curis.ku.dk/portal/da/publications/predicting-efficacy-of-epirubicin-by-a-multigene-assay-in-advanced-breast-cancer-within-a-danish-breast-cancer-cooperative-group-dbcg-cohort(d94324d4-b6ee-484b-9f67-4ebcfeaf6560).html